GEN Exclusives

More »

The Lists

More »
Jul 8, 2013

Top 15 Vaccines of 2012

These top-sellers could be the booster shots the industry needs.

Top 15 Vaccines of 2012

Relatively few drug/vaccine developers are responsible for the top sellers on this list. [© Robert Hoetink - Fotolia.com]

  • #8. Menactra

    Meningococcal polysaccharide (serogroups A, C, Y, and W-135) diphtheria toxoid conjugate vaccine

    2012 sales: €564 million ($735 million)1,2

    2011 sales: €427 million ($557 million)1,2,7

    % year-to-year sales growth: 32.1%

    Developer/Sponsor: Sanofi and Sanofi Pasteur MSD

    Indications: Active immunization of individuals nine months through 55 years of age for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135

  • #7. Varivax

    Varicella virus vaccine live

    2012 sales: $846 million4

    2011 sales: $831 million4

    % year-to-year sales growth: 1.8%

    Developer/Sponsor: Merck & Co. and Sanofi Pasteur MSD

    Indications: Active immunization of persons 12 months of age and older; optional second dose for children 12 months to 12 years of age

  • #6. Hepatitis franchise

    Includes: Hepatitis A vaccine, inactivated (Havrix); Hepatitis A inactivated and hepatitis B (recombinant) vaccine (Twinrix); Hepatitis B vaccine (recombinant)(Engerix-B)

    2012 sales: £646 million ($986 million)1,8

    2011 sales: $688 million ($1.050 billion)1,8

    % year-to-year sales growth: -6.1%

    Developer/Sponsor: GlaxoSmithKline

    Indications: Active immunization against disease caused by hepatitis A virus for persons ≥12 months of age (Havrix); active immunization of persons 18 years of age or older against disease caused by hepatitis A virus and infection by all known subtypes of hepatitis B virus (Twinrix); and immunization against infection caused by all known subtypes of hepatitis B virus (Engerix-B)

  • #5. Fluzone®, Fluzone High-Dose and Fluzone Intradermal /Vaxigrip®/ Mutagrip®

    Influenza virus vaccine

    2012 sales: €884 million ($1.152 billion)1,2

    2011 sales: €826 million ($1.077 million)1,2

    % year-to-year sales growth: 7.0%

    Developer/Sponsor: Sanofi and Sanofi Pasteur MSD

    Indications: Active immunization of persons six months of age and older against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. Fluzone High-Dose is indicated for active immunization of persons 65 years of age and older against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine; Fluzone Intradermal indicated for active immunization for use in adults 18 through 64 years of age against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine

  • #4. Infanrix/Pediarix

    Diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant) and inactivated poliovirus vaccine combined

    2012 sales: £775 million ($1.183 billion)1

    2011 sales: £690 million ($1.053 billion)1

    % year-to-year sales growth: 12.3%

    Developer/Sponsor: GlaxoSmithKline

    Indications: Active immunization against diphtheria, tetanus, pertussis, infection caused by all known subtypes of hepatitis B virus, and poliomyelitis. Approved for use as a three-dose series in infants born of hepatitis B surface antigen (HBsAg)-negative mothers; may be given as early as six weeks of age through six years of age (prior to the seventh birthday)

  • #3. PENTAct-HIB

    Hemophilus influenzae type b polysaccharide conjugated to tetanus protein, diphtheria, tetanus, pertussis, and inactivated poliovirus vaccines (types 1, 2, and 3)

    2012 sales: $1.522 billion9,10

    2011 sales: $1.496 billion9,10

    % year-to-year sales growth: 1.7%

    Developer/Sponsor: Sanofi and Sanofi Pasteur MSD

    Indications: Prevention of invasive infections, e.g., meningitis, septicemia, epiglottitis caused by H influenzae type B, diphtheria, pertussis, tetanus, and poliomyelitis

  • #2. Gardasil®

    Human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant

    2012 sales: $1.900 billion11

    2011 sales: $1.445 billion12

    % year-to-year sales growth: 31.5%

    Developer/Sponsor: Merck & Co. and Sanofi Pasteur MSD

    Indications: Prevention of vulvar and vaginal cancer; prevention of the following diseases caused by human papillomavirus (HPV) types 6, 11, 16, and 18: cervical cancer; genital warts (condyloma acuminata) and the following precancerous or dysplastic lesions: cervical adenocarcinoma in situ (AIS); cervical intraepithelial neoplasia (CIN) grade 2 and grade 3; vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3; vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3; and CIN grade 1. Also, prevention of genital warts caused by HPV types 6 and 11 in boys and men nine through 26 years of age; and prevention of anal cancer and associated precancerous lesions due to human papillomavirus (HPV) types 6, 11, 16, and 18 in people ages nine through 26 years.

  • #1. Prevnar 13®/Prevenar 13

    Pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein)

    2012 sales: $3.718 billion

    2011 sales: $3.657 billion

    % year-to-year sales growth: 1.7%

    Developer/Sponsor: Pfizer

    Indications: Prevention of: pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in persons 50 years of age or older; invasive disease caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in children six weeks through 17 years of age; otitis media caused by S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F for use in children six weeks through five years of age


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Companion Animal Care

Do you think Americans spend too much on companion animal care?